A Congressional letter is asking NIH to describe the procedures employed for rooting out sexual misconduct committed by advisors.
First published in 1977, Cancer Crusade: The Story of the National Cancer Act of 1971, is a dispassionate legislative history—a book you can trust.
Directors of the first three NCI-designated Comprehensive Cancer Centers are learning from the past, starting with the National Cancer Act, and mapping an equitable future for oncology.
The vast majority of hospitals in the United States—up to 80%—treat patient populations that are disproportionately white, U.S. News & World Report said, unveiling a new suite of health equity measures earlier this week.
When Ben Harder and his team of health analysts at U.S. News & World Report developed a suite of health equity measures for America’s hospitals, they expected to find some level of disparity, but nothing prepared them for the shocking magnitude of inequity they uncovered.
To comprehend the significance of disparities articulated in the U.S. News study and define the scorecards’ impact on bragging rights at cancer centers, The Cancer Letter asked four leaders in oncology to evaluate the health equity measures.
Institutions will be required to report sexual misconduct to NIH if House committee bill becomes law
Institutions receiving NIH funds through grants or cooperative agreements would be required—by federal law—to notify the NIH director when a principal investigator or other key personnel are removed or disciplined for “harassment, bullying, retaliation, or hostile working conditions.”
A House appropriations subcommittee voted to increase NIH’s FY2022 budget by $6.5 billion—to $46.43 billion—which falls $2.5 billion short of President Joe Biden’s request for NIH.
The FY22 budget proposed by the White House doesn’t include sufficient funds to sustainably support NCI researchers, even though the proposal includes the largest ever funding increase for NIH, the American Association for Cancer Research said in a letter to House appropriators.
From 2015 to 2018, the overall cancer death rate in the United States fell by 2.3% per year for men and 2.1% per year for women—an unprecedented drop, led by accelerated decline in deaths from lung cancer and melanoma.
